British Hypertension Society guidelines for hypertension management 1999: summary

BMJ 1999;319:630-635 ( 4 September )

Education and debate

British Hypertension Society guidelines for hypertension management 1999: summary

Lawrence E Ramsay, professor of clinical pharmacology and therapeutics ^a, Bryan Williams, professor of medicine ^b, G Dennis Johnston, professor of clinical pharmacology ^c, Graham A MacGregor, professor of cardiovascular medicine ^d, Lucilla Poston, professor of fetal medicine ^e, John F Potter, professor of medicine for the elderly ^b, Neil R Poulter, director, cardiovascular studies unit ^f, Gavin Russell, consultant renal physician ^g.

^a University of Sheffield, Sheffield S10 2TN, ^b University of Leicester School of Medicine, Leicester Royal Infirmary, Leicester LE2 7LX, ^c Queen's University of Belfast, Belfast BT7 1NN, ^d Department of Medicine, St George's Hospital, London SW17 0RE, ^e Department of Obstetrics and Gynaecology, St Thomas's Hospital, London SE1 7EH, ^f Imperial College School of Medicine, London W2 1NY, ^g North Staffordshire Royal Infirmary, Stoke on Trent ST4 7LN

Correspondence to: B Williams bw17@leicester.ac.uk

The first 150 words of the full text of this article appear below.

This article summarises the new British Hypertension Society guidelines for management of hypertension, which have been publishedin full.¹ Since the previous guidelines ² ³ much new evidencehas emerged on optimal blood pressure targets⁴; managementof hypertension in diabetic patients^4-7; treatment of isolatedsystolic hypertension⁸; comparison of the antihypertensiveefficacy and tolerability of different drug classes^9-11; the roleof non-pharmacological measures for prevention ¹² ¹³ and treatmentof hypertension¹⁴; and additional benefits associated with theuse of aspirin andstatins.

Of concern is that national surveys continue to reveal incomplete detection, treatment, and control of hypertension.¹⁵ Furthermore,treated hypertensive patients still die prematurely from cardiovasculardisease.¹⁶ These guidelines aim to present the best currentlyavailable evidence on hypertension management and their implementation.

Table Removed (Available Only in the Full Text)

Table Removed (Available Only in the Full Text)

Blood pressure measurement

All adults should have their blood pressure measured routinely at least every five years until the age of 80 years. Thosewith high-normal values (135-139/85-89 mm Hg) . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

Relevant Articles

Tackling therapeutic inertia: role of treatment data in quality indicators: Bruce Guthrie, Melanie Inkster, and Tom Fahey
BMJ 2007 335: 542-544. [Extract] [Full Text] [PDF]

Aspirin for primary prevention: Lawrence E Ramsay, Philemon S Sanmuganathan, Erica J Wallis, Peter R Jackson, and Abdullah Alkhenizan
BMJ 2000 321: 1472. [Extract] [Full Text]

Management of hypertension: John Wilding, Gareth Williams, Garfield Drummond, Tom Marshall, Andrew Rouse, John Eisenberg, Angela Hey, Tahseen A Chowdhury, Hogne Sandvik, Michael Stewart, N J Sharvill, Bruce M Psaty, Curt D Furberg, Lawrence E Ramsay, Bryan Williams, John F Potter, G Dennis Johnston, Graham A MacGregor, Lucilla Poston, Neil R Poulter, and Gavin Russell
BMJ 2000 320: 576. [Extract] [Full Text] [PDF]

British guidelines on managing hypertension: Bruce M Psaty and Curt D Furberg
BMJ 1999 319: 589-590. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

Edwards, C J, Syddall, H, Goswami, R, Goswami, P, Dennison, E M, Arden, N K, Cooper, C, on behalf of the Hertfordshire Cohort Study Group, (2007). The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 93: 1263-1267 [Abstract] [Full text]
Guthrie, B., Inkster, M., Fahey, T. (2007). Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ 335: 542-544 [Full text]
Verberk, W. J., Kroon, A. A., Kessels, A. G.H., de Leeuw, P. W. (2005). Home Blood Pressure Measurement: A Systematic Review. J Am Coll Cardiol 46: 743-751 [Abstract] [Full text]
Burns, G. E. (2005). Challenges of teaching EBM. CMAJ 172: 1423-1424 [Full text]
Smith, G. D., Lawlor, D. A., Harbord, R., Timpson, N., Rumley, A., Lowe, G. D.O., Day, I. N.M., Ebrahim, S. (2005). Association of C-Reactive Protein With Blood Pressure and Hypertension: Life Course Confounding and Mendelian Randomization Tests of Causality. Arterioscler. Thromb. Vasc. Bio. 25: 1051-1056 [Abstract] [Full text]
Wong, T. Y., Mitchell, P. (2004). Hypertensive Retinopathy. NEJM 351: 2310-2317 [Full text]
Wiggins, B. S., Spinler, S. (2004). Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. Journal of Pharmacy Practice 17: 347-369 [Abstract]
Feher, M D (2004). Diabetes: preventing coronary heart disease in a high risk group. Heart 90: iv18-iv21 [Abstract] [Full text]
Evans, N (2004). Managing the cost of cardiovascular prevention in primary care. Heart 90: iv26-iv28 [Abstract] [Full text]
McKerracher, A (2004). Treating to hypertension targets. Heart 90: iv33-iv35 [Abstract] [Full text]
Shah, S U, Anjum, S, Littler, W A (2004). Use of diuretics in cardiovascular disease: (2) hypertension. Postgrad. Med. J. 80: 271-276 [Abstract] [Full text]
Hense, H.-W. (2004). Observations, predictions and decisions--assessing cardiovascular risk assessment. Int J Epidemiol 33: 235-239 [Full text]
Howell, S. J., Sear, J. W., Foex, P. (2004). Hypertension, hypertensive heart disease and perioperative cardiac risk{dagger}. Br J Anaesth 92: 570-583 [Abstract] [Full text]
Laurent, S. (2004). Guidelines from the British Hypertension Society. BMJ 328: 593-594 [Full text]
Borzecki, A. M., Wong, A. T., Hickey, E. C., Ash, A. S., Berlowitz, D. R. (2003). Hypertension Control: How Well Are We Doing?. Arch Intern Med 163: 2705-2711 [Abstract] [Full text]
Stanton, A., Jensen, C., Nussberger, J., O'Brien, E. (2003). Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren. Hypertension 42: 1137-1143 [Abstract] [Full text]
Oakeshott, P., Kerry, S., Austin, A., Cappuccio, F. (2003). Is there a role for nurse-led blood pressure management in primary care?. Fam Pract 20: 469-473 [Abstract] [Full text]
Brown, M. J (2003). Review: Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. British Journal of Diabetes & Vascular Disease 3: 245-251 [Abstract]
Jacobson, L., Elwyn, G., Robling, M., Jones, R. T. (2003). Error and safety in primary care: no clear boundaries. Fam Pract 20: 237-241 [Abstract] [Full text]
Hense, H.-W., Schulte, H., Lowel, H., Assmann, G., Keil, U. (2003). Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24: 937-945 [Abstract] [Full text]
Wong, T. Y., Klein, R., Duncan, B. B., Nieto, F. J., Klein, B. E.K., Couper, D. J., Hubbard, L. D., Sharrett, A. R. (2003). Racial Differences in the Prevalence of Hypertensive Retinopathy. Hypertension 41: 1086-1091 [Abstract] [Full text]
Tu, K., Mamdani, M. M., Jacka, R. M., Forde, N. J., Rothwell, D. M., Tu, J. V. (2003). The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 168: 553-557 [Abstract] [Full text]
August, P. (2003). Initial Treatment of Hypertension. NEJM 348: 610-617 [Full text]
Lawlor, D A, Bedford, C, Taylor, M, Ebrahim, S (2003). Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J. Epidemiol. Community Health 57: 134-140 [Abstract] [Full text]
Williams, B. (2003). Drug treatment of hypertension. BMJ 326: 61-62 [Full text]
Stott, P. (2003). Quality driven management of tablet-treated type 2 diabetes -- potential increases in GP practice prescribing costs. British Journal of Diabetes & Vascular Disease 3: 64-68 [Abstract]
Fisher, M. (2003). Prevention of macrovascular complications. Eur Heart J Suppl 5: B21-B26 [Abstract]
Cappuccio, F. P, Oakeshott, P., Strazzullo, P., Kerry, S. M (2002). Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 325: 1271-1271 [Abstract] [Full text]
(2002). Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function?. Heart 88: 222-228 [Abstract] [Full text]
Wallis, E. J, Ramsay, L. E, Jackson, P. R (2002). CARDIOVASCULAR AND CORONARY RISK ESTIMATION IN HYPERTENSION MANAGEMENT. Heart 88: 306-312 [Full text]
Duncan, B B, Wong, T Y, Tyroler, H A, Davis, C E, Fuchs, F D (2002). Hypertensive retinopathy and incident coronary heart disease in high risk men. Br. J. Ophthalmol. 86: 1002-1006 [Abstract] [Full text]
Nanchahal, K., Duncan, J. R, Durrington, P. N, Jackson, R. T (2002). Analysis of predicted coronary heart disease risk in England based on Framingham study risk appraisal models published in 1991 and 2000. BMJ 325: 194-195 [Full text]
Vasan, R.S., Levy, D. (2002). Rates of progression to hypertension among non-hypertensive subjects: implications for blood pressure screening. Eur Heart J 23: 1067-1070 [Full text]
Kothari, V., Stevens, R. J., Adler, A. I., Stratton, I. M., Manley, S. E., Neil, H. A., Holman, R. R. (2002). UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine. Stroke 33: 1776-1781 [Abstract] [Full text]
Law, M R, Wald, N J (2002). Risk factor thresholds: their existence under scrutiny. BMJ 324: 1570-1576 [Full text]
Horton, R. (2002). Postpublication Criticism and the Shaping of Clinical Knowledge. JAMA 287: 2843-2847 [Abstract] [Full text]
Motwani, J. G (2002). Review: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. Journal of Renin-Angiotensin-Aldosterone System 3: 72-78 [Abstract]
Swift, P. A, MacGregor, G. A (2002). Review: The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?. Journal of Renin-Angiotensin-Aldosterone System 3: 103-108 [Abstract]
Lauer, M. S. (2002). Aspirin for Primary Prevention of Coronary Events. NEJM 346: 1468-1474 [Full text]
Rabindranath, K S, Anderson, N R, Gama, R, Holland, M R (2002). Comparative evaluation of the new Sheffield table and the modified joint British societies coronary risk prediction chart against a laboratory based risk score calculation. Postgrad. Med. J. 78: 269-272 [Abstract] [Full text]
Meredith, P. A, Trenkwalder, P. (2002). Therapy in the elderly hypertensive. Journal of Renin-Angiotensin-Aldosterone System 3: S49-S56 [Abstract]
Roeters van Lennep, J. E, Westerveld, H.T., Erkelens, D.W., van der Wall, E. E (2002). Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 53: 538-549 [Abstract] [Full text]
Jackson, P. R., Ramsay, L. E. (2002). First-line treatment for hypertension. Eur Heart J 23: 179-182 [Full text]
Garcia-Pena, C., Thorogood, M., Armstrong, B., Reyes-Frausto, S., Munoz, O. (2001). Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. Int J Epidemiol 30: 1485-1491 [Abstract] [Full text]
Black, H. R., Elliott, W. J., Weber, M. A., Frishman, W. H., Strom, J. A., Liebson, P. R., Hwang, C. T., Ruff, D. A., Montoro, R., DeQuattro, V., Zhang, D., Schleman, M. M., Klibaner, M. I. (2001). One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. Hypertension 38: 1118-1123 [Abstract] [Full text]
Ferrucci, L., Furberg, C. D., Penninx, B. W.J.H., DiBari, M., Williamson, J. D., Guralnik, J. M., Chen, J. G., Applegate, W. B., Pahor, M. (2001). Treatment of Isolated Systolic Hypertension Is Most Effective in Older Patients With High-Risk Profile. Circulation 104: 1923-1926 [Abstract] [Full text]
Montgomery, A A, Fahey, T (2001). How do patients' treatment preferences compare with those of clinicians?. Qual Saf Health Care 10: i39-43 [Abstract] [Full text]
Hippisley-Cox, J., Pringle, M. (2001). General practice workload implications of the national service framework for coronary heart disease: cross sectional survey. BMJ 323: 269-270 [Full text]
Allan, G., Chalmers, J., Duncan, C., Jones, I. G, Campbell, I. W (2001). Audit of mortality in type 2 diabetes mellitus. British Journal of Diabetes & Vascular Disease 1: 52-54
Brown, M. J (2001). HYPERTENSION: Matching the right drug to the right patient in essential hypertension. Heart 86: 113-120 [Full text]
Dix, P., Howell, S. (2001). Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery. Br J Anaesth 86: 789-793 [Abstract] [Full text]
Foggensteiner, L., Mulroy, S., Firth, J. (2001). Management of diabetic nephropathy. JRSM 94: 210-217 [Full text]
Wahid, S. T., Baines, L. A., Savopoulos, L., Connolly, V. M., Kelly, W. F., Bilous, R. W. (2001). Longitudinal Analysis of Blood Pressure, Lipid, and Glycemic Control in Diabetic Patients With Nephropathy Attending a Hospital Outpatient Clinic and Their Relationship to Renal Function, Mortality, and Cardiovascular Morbidity. Diabetes Care 24: 789-790 [Full text]
Bulpitt, C. J (2001). Review: The management of the elderly with hypertension. Journal of Renin-Angiotensin-Aldosterone System 2: 11-13
Sever, P. S, Limmie Chang, C. (2001). Discordant responses to two classes of drugs acting on the renin-angiotensin system. Journal of Renin-Angiotensin-Aldosterone System 2: 25-30 [Abstract]
Sanmuganathan, P S, Ghahramani, P, Jackson, P R, Wallis, E J, Ramsay, L E (2001). Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85: 265-271 [Abstract] [Full text]
British Cardiac Society Guidelines and Medical Pra, , Royal College of Physicians Clinical Effectiveness, (2001). Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart 85: 133-142 [Full text]
Meade, T W, Brennan, P J (2001). Authors' reply on aspirin for primary prevention. BMJ 322: 171-171 [Full text]
, S. (2001). Recent advances: Geriatric. BMJ 322: 86-89 [Full text]
Ashton, W.D, Nanchahal, K, Wood, D.A (2001). Body mass index and metabolic risk factors for coronary heart disease in women. Eur Heart J 22: 46-55 [Abstract]
Pahor, M., Psaty, B. M., Alderman, M. H., Furberg, C. D. (2001). Meta-analysis of Hypertension Trials in Diabetic Patients: Response to Parving and Rossing. Diabetes Care 24: 178-180 [Full text]
Jones, A F, Walker, J, Jewkes, C, Game, F L, Bartlett, W A, Marshall, T, Bayly, G R (2001). Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart 85: 37-43 [Abstract] [Full text]
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W, Cooper, M. E (2000). Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444 [Abstract] [Full text]
Ramsay, L. E, Sanmuganathan, P. S, Wallis, E. J, Jackson, P. R, Alkhenizan, A. (2000). Aspirin for primary prevention. BMJ 321: 1472-1472 [Full text]
Melville, A, Richardson, R, Lister-Sharp, D, McIntosh, A (2000). Complications of diabetes: renal disease and promotion of self-management. Qual Saf Health Care 9: 257-263 [Full text]
Van den Hoogen, P.C.W., Seidell, J.C., Menotti, A., Kromhout, D. (2000). Blood pressure and long-term coronary heart disease mortality in the Seven Countries Study: implications for clinical practice and public health. Eur Heart J 21: 1639-1642
Psaty, B. M., Furberg, C. D., Pahor, M., Alderman, M., Kuller, L. H. (2000). National Guidelines, Clinical Trials, and Quality of Evidence. Arch Intern Med 160: 2577-2580 [Full text]
Malaviya, A N, Mourou, M (2000). Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)?. Lupus 9: 561-562
Meade, T W, Brennan, P J (2000). Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321: 13-17 [Abstract] [Full text]
Williams, B. (2000). The renin angiotensin system and cardiovascular disease: hope or hype?. Journal of Renin-Angiotensin-Aldosterone System 1: 142-146
Steel, N. (2000). Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ 320: 1446-1447 [Full text]
O'Brien, E., Coats, A., Owens, P., Petrie, J., Padfield, P. L, Littler, W. A, de Swiet, M., Mee, F. (2000). Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 320: 1128-1134 [Full text]
Bulpitt, C.J. (2000). Controlling hypertension in the elderly. QJM 93: 203-205 [Full text]
Jackson, R. (2000). Guidelines on preventing cardiovascular disease in clinical practice. BMJ 320: 659-661 [Full text]
Wallis, E. J, Ramsay, L. E, Haq, I. U., Ghahramani, P., Jackson, P. R, Rowland-Yeo, K., Yeo, W. W (2000). Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 320: 671-676 [Abstract] [Full text]
Baker, S., Priest, P., Jackson, R. (2000). Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 320: 680-685 [Abstract] [Full text]
Wilding, J., Williams, G., Drummond, G., Marshall, T., Rouse, A., Eisenberg, J., Hey, A., Chowdhury, T. A, Sandvik, H., Stewart, M., Sharvill, N J, Psaty, B. M, Furberg, C. D, Ramsay, L. E, Williams, B., Potter, J. F, Johnston, G D., MacGregor, G. A, Poston, L., Poulter, N. R, Russell, G. (2000). Management of hypertension. BMJ 320: 576-576 [Full text]
Willis, C., Gaffney, B., Yarnell, J. (2000). Hypertension: what do people think? A survey in Northern Ireland of public knowledge and attitudes concerning high blood pressure. Health Education Journal 59: 308-314 [Abstract]
Psaty, B. M, Furberg, C. D (1999). British guidelines on managing hypertension. BMJ 319: 589-590 [Full text]

Rapid Responses:

Read all Rapid Responses

International community dispute BP targets: David Lewis
bmj.com, 4 Sep 1999 [Full text]
Guidelines-- of no benefit if they cannot be implemented: Robert Fleetcroft
bmj.com, 5 Sep 1999 [Full text]
Optimal target pressure not supported by strength A evidence: Hogne Sandvik
bmj.com, 4 Sep 1999 [Full text]
BRITISH HYPERTENSION SOCIETY GUIDELINES: Tahseen A Chowdhury
bmj.com, 7 Sep 1999 [Full text]
Role of the laboratory in disseminating and implementing guidelines: R Gama
bmj.com, 9 Sep 1999 [Full text]
Treating hypertension with lifestyle measures: Aim for modest weight loss, not �ideal body weight�: John Wilding, et al.
bmj.com, 8 Sep 1999 [Full text]
How many drugs is enough?: David Payne
bmj.com, 11 Sep 1999 [Full text]
BRITISH HYPERTENSION SOCIETY GUIDELINES: Gary Drybala
bmj.com, 16 Sep 1999 [Full text]
British Hypertension Society Guidelines: Garfield Drummond
bmj.com, 6 Oct 1999 [Full text]
Ownership and uptake of guidelines: Phil Taylor
bmj.com, 7 Oct 1999 [Full text]
British Guidelines on Hypertension Do not consider Workload Implications In Primary Care: John Eisenberg
bmj.com, 16 Oct 1999 [Full text]
Target organ assessment in nurse run clinics: Pam Sim
bmj.com, 2 Nov 1999 [Full text]
Guidelines do not address marginal cost benefit: Michael Moore
bmj.com, 17 Nov 1999 [Full text]
Management of Hypertension.: Tom Black
bmj.com, 16 Nov 1999 [Full text]